Ratings Valeo Pharma Inc.

Equities

VPH

CA91915B1085

Market Closed - Toronto S.E. Other stock markets 04:00:00 2024-05-16 pm EDT			5-day change	1st Jan Change
0.1 ^CAD	0.00%		+5.26%	-44.44%

Apr. 25	Transcript : Valeo Pharma Inc. - Shareholder/Analyst Call
Mar. 22	Valeo Pharma Inc. Announces Appointment of Al Moghaddam to Board of Directors	CI

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Over the past four months, analysts' average price target has been revised downwards significantly.
The average consensus view of analysts covering the stock has deteriorated over the past four months.
Over the past twelve months, analysts' consensus has been significantly revised downwards.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
VALEO PHARMA INC.	-44.44%	7.25M	-
ELI LILLY AND COMPANY	+32.36%	694B	C+
NOVO NORDISK A/S	+29.59%	593B	B
JOHNSON & JOHNSON	-1.60%	371B	C+
MERCK & CO., INC.	+20.07%	331B	B-
ABBVIE INC.	+6.04%	290B	C+
ASTRAZENECA PLC	+14.51%	239B	B+
ROCHE HOLDING AG	-3.48%	209B	A+
NOVARTIS AG	+10.07%	209B	B-
AMGEN INC.	+9.27%	169B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes